Dr. Christophe Lahorte holds a Master’s degree in Pharmaceutical Sciences and a PhD in Pharmaceutical Sciences from the University of Gent. He has extensive experience in academic research, having worked on the development of new radiopharmaceuticals in collaboration with the Nuclear Medicine Department at the University Hospital Gent. Since 2004, Dr. Lahorte has been with the Federal Agency of Medicines and Health Products (FAMHP), where he has played a key role in the quality assessment of clinical trial applications and paediatric investigation plans. In 2009, he became head of FAMHP’s Unit for National Scientific-Technical Advice & Knowledge Management, and in 2017, he was appointed Head of the National Innovation Office. His work focuses on supporting and guiding innovators developing new drugs and medical technologies in Belgium and Europe. Dr. Lahorte is also involved in several EU projects, including the “Accelerating Clinical Trials in the EU” initiative and the EU4Health Joint Action on capacity building. He is a member of several EU-level working groups, including those on drug repurposing, borderline products, and emerging technologies.
